Dana A. Kennedy

Pfizer (United States) — United States

Medicine · Health Sciences

26h-index6.3kcitations73works8.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(46), Cutaneous lymphoproliferative disorders research(27), CAR-T cell therapy research(22), HER2/EGFR in Cancer Research(12), Monoclonal and Polyclonal Antibodies Research(11)

Publications73 total

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
The Lancet·2025· 10 cited
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial
The Lancet·2025· 16 cited
Abstract CT102: Exploring the tumor molecular landscape associated with<i>TMPRSS2-ERG</i>: A post hoc analysis from the phase 3 TALAPRO-2 study of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research·2025
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
Journal of Clinical Oncology·2025· 8 cited
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
Journal of Clinical Oncology·2025· 23 cited
Talazoparib Plus Enzalutamide in Hrr-Deficient Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Results from the Phase 3 Talapro-2 Trial
SSRN Electronic Journal·2025Open Access
Shakespeare’s Refugees
Cambridge University Press eBooks·2024
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 1 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Tables 1 - 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 1 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Tables 1 - 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
The Role of Dietician-Nutritionist in PACE
2022
Traumatic Brain Injury, Abuse, and Poor Sustained Attention in Youth and Young Adults Who Previously Experienced Foster Care
Neurotrauma Reports·2021· 6 citedOpen Access
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Blood·2018· 64 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Nancy L. Bartlett(27), Ranjana H. Advani(18), Michelle A. Fanale(18), Eric L. Sievers(17), Andrei R. Shustov(17), Joseph D. Rosenblatt(16), Tim Illidge(15), Andres Forero‐Torres(13), Barbara Pro(13), Joseph M. Connors(12), Anas Younes(8), Ajay K. Gopal(7), Radhakrishnan Ramchandren(7), Pauline Brice(7), Jeffrey Matous(7), Emily K. Larsen(6), Yin Yang(6), Dirk Huebner(6), Andrew Davies(5), Megan M. O’Meara(5)